These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

337 related articles for article (PubMed ID: 9713503)

  • 1. Rapid development of drug resistance in human ovarian tumor xenografts after a single treatment with melphalan in Vivo.
    Caffrey PB; Zhang Y; Frenkel GD
    Anticancer Res; 1998; 18(4C):3021-5. PubMed ID: 9713503
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of human ovarian tumor xenografts with selenite prevents the melphalan-induced development of drug resistance.
    Caffrey PB; Frenkel GD
    Anticancer Res; 1998; 18(4C):3017-20. PubMed ID: 9713502
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of a panel of 15 human ovarian cancer xenografts for drug screening and determination of the role of the glutathione detoxification system.
    Kolfschoten GM; Pinedo HM; Scheffer PG; Schlüper HM; Erkelens CA; Boven E
    Gynecol Oncol; 2000 Mar; 76(3):362-8. PubMed ID: 10684711
    [TBL] [Abstract][Full Text] [Related]  

  • 4. d,l-buthionine-(S,R)-sulfoximine potentiates in vivo the therapeutic efficacy of doxorubicin against multidrug resistance protein-expressing tumors.
    Vanhoefer U; Cao S; Minderman H; Toth K; Skenderis BS; Slovak ML; Rustum YM
    Clin Cancer Res; 1996 Dec; 2(12):1961-8. PubMed ID: 9816155
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel phosphonium salts display in vitro and in vivo cytotoxic activity against human ovarian cancer cell lines.
    Manetta A; Gamboa G; Nasseri A; Podnos YD; Emma D; Dorion G; Rawlings L; Carpenter PM; Bustamante A; Patel J; Rideout D
    Gynecol Oncol; 1996 Feb; 60(2):203-12. PubMed ID: 8631539
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Potentiation of melphalan cytotoxicity in human ovarian cancer cell lines by glutathione depletion.
    Green JA; Vistica DT; Young RC; Hamilton TC; Rogan AM; Ozols RF
    Cancer Res; 1984 Nov; 44(11):5427-31. PubMed ID: 6488194
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevention of the development of melphalan resistance in vitro by selenite.
    Caffrey PB; Zhu M; Frenkel GD
    Biol Trace Elem Res; 1998 Dec; 65(3):187-95. PubMed ID: 9892492
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Establishment of a melphalan-resistant rhabdomyosarcoma xenograft with cross-resistance to vincristine and enhanced sensitivity following buthionine sulfoximine-mediated glutathione depletion.
    Rosenberg MC; Colvin OM; Griffith OW; Bigner SH; Elion GB; Horton JK; Lilley E; Bigner DD; Friedman HS
    Cancer Res; 1989 Dec; 49(24 Pt 1):6917-22. PubMed ID: 2582434
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prostate carcinoma response to cytotoxic therapy: in vivo resistance.
    Teicher BA; Kakeji Y; Ara G; Herbst RS; Northey D
    In Vivo; 1997; 11(6):453-61. PubMed ID: 9509295
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Collateral susceptibility of adriamycin-, melphalan- and cisplatin-resistant human ovarian tumor cells to bleomycin.
    Tsuruo T; Hamilton TC; Louie KG; Behrens BC; Young RC; Ozols RF
    Jpn J Cancer Res; 1986 Sep; 77(9):941-5. PubMed ID: 2429947
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mechanisms of cross-resistance between radiation and antineoplastic drugs.
    Ozols RF; Masuda H; Hamilton TC
    NCI Monogr; 1988; (6):159-65. PubMed ID: 3352759
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Elevated DNA polymerase alpha, DNA polymerase beta, and DNA topoisomerase II in a melphalan-resistant rhabdomyosarcoma xenograft that is cross-resistant to nitrosoureas and topotecan.
    Friedman HS; Dolan ME; Kaufmann SH; Colvin OM; Griffith OW; Moschel RC; Schold SC; Bigner DD; Ali-Osman F
    Cancer Res; 1994 Jul; 54(13):3487-93. PubMed ID: 8012971
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combined effects of buthionine sulfoximine and cepharanthine on cytotoxic activity of doxorubicin to multidrug-resistant cells.
    Kisara S; Furusawa S; Murata R; Ogata M; Hikichi N; Takayanagi Y; Sasaki K
    Oncol Res; 1995; 7(3-4):191-200. PubMed ID: 8555653
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of glutathione (GSH) in determining sensitivity to platinum drugs in vivo in platinum-sensitive and -resistant murine leukaemia and plasmacytoma and human ovarian carcinoma xenografts.
    Goddard P; Valenti M; Kelland LR
    Anticancer Res; 1994; 14(3A):1065-70. PubMed ID: 8074451
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Transforming growth factor-beta 1 overexpression produces drug resistance in vivo: reversal by decorin.
    Teicher BA; Ikebe M; Ara G; Keyes SR; Herbst RS
    In Vivo; 1997; 11(6):463-72. PubMed ID: 9509296
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Brostallicin, a novel anticancer agent whose activity is enhanced upon binding to glutathione.
    Geroni C; Marchini S; Cozzi P; Galliera E; Ragg E; Colombo T; Battaglia R; Howard M; D'Incalci M; Broggini M
    Cancer Res; 2002 Apr; 62(8):2332-6. PubMed ID: 11956092
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Selenium compounds prevent the induction of drug resistance by cisplatin in human ovarian tumor xenografts in vivo.
    Caffrey PB; Frenkel GD
    Cancer Chemother Pharmacol; 2000; 46(1):74-8. PubMed ID: 10912582
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increased glutathione level is not involved in enhanced bleomycin sensitivity in cisplatin-resistant 2780CP cells.
    Tanaka T; Kurokawa H; Matsuno K; Matsumoto S; Hayashida Y
    Anticancer Res; 2008; 28(5A):2663-8. PubMed ID: 19035292
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Acute in vivo resistance in high-dose therapy.
    Teicher BA; Ara G; Keyes SR; Herbst RS; Frei E
    Clin Cancer Res; 1998 Feb; 4(2):483-91. PubMed ID: 9516940
    [TBL] [Abstract][Full Text] [Related]  

  • 20. cis-Amminedichloro(2-methylpyridine) platinum(II) (AMD473), a novel sterically hindered platinum complex: in vivo activity, toxicology, and pharmacokinetics in mice.
    Raynaud FI; Boxall FE; Goddard PM; Valenti M; Jones M; Murrer BA; Abrams M; Kelland LR
    Clin Cancer Res; 1997 Nov; 3(11):2063-74. PubMed ID: 9815598
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.